• Bernard Swynghedauw
Part of the Practical Issues in Geriatrics book series (PIG)


Ageing is the time-dependent functional decline that affects a living species. Senescence is as complicated as life. The mean lifespan of humans has been increasing for a century and population ageing has shaped a totally new medical landscape.


Life Senescence Seclusion Lifespan Pets 


  1. 1.
    Lopez-Otin C, et al. The hallmarks of ageing. Cell. 2013;153:1194.CrossRefGoogle Scholar
  2. 2.
    Swynghedauw B. L’homme malade de lui-même. Paris: Belin Editions; 2015.Google Scholar
  3. 3.
    Barbi E, et al. The plateau of human mortality : demography of longevity pioneers. Science. 2018;360:1459–61. (see also comments by E Dolgin, in Nature Infocus news 2018, 559, 14-15).CrossRefGoogle Scholar
  4. 4.
    Wachter KW, et al. Evolutionary shaping of demographic schedules. PNAS. 2014;111(Suppl 3):10846–53.CrossRefGoogle Scholar
  5. 5.
    Belmin J, et col. ed. Gériatrie. Elsevier/Masson; 2009. 835 pp.Google Scholar
  6. 6.
    Brondello JM, et al. La sénescence cellulaire. Un nouveau mythe de Janus? Méd/Sci. 2012;28:288–94.Google Scholar
  7. 7.
    Lutz W, et al. The coming acceleration of global population ageing. Nature. 2008;451:716–9.CrossRefGoogle Scholar
  8. 8.
    GBDS, Global Burden of Disease 2016. Disease and Injury incidence and prevalence collaborators, Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the GBDS 2016. Lancet. 2016;390:1211–59.Google Scholar
  9. 9.
    GBDS, Global Burden of Disease 2016. DALYS and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYS) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the GBDS 2016. Lancet. 2016;390:1260–344.Google Scholar
  10. 10.
    Ponthière G. Economie du vieillissement. Paris: La Découverte; 2017.Google Scholar
  11. 11.
    Tabuteau D. Démocratie sanitaire. Les nouveaux défits de la politique sanitaire. Paris: Odile Jacob; 2013.Google Scholar
  12. 12.
    Koshland D. The seven pillars of life. Science. 2003;295:2215.CrossRefGoogle Scholar
  13. 13.
    Baker DJ, et al. Clearance of p16Ink4a-positive cells delays ageing-associated disorders. Nature. 2011;479:232–6.CrossRefGoogle Scholar
  14. 14.
    Bussian TJ, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578–82.CrossRefGoogle Scholar
  15. 15.
    Childs BG, et al. Cellular senescence in ageing and age-related disease: from mechanisms to theory. Nat Med. 2015;21:1424–35.CrossRefGoogle Scholar
  16. 16.
    Childs BG, et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016;354:472–7.CrossRefGoogle Scholar
  17. 17.
    Deursen van JM. The role of senescent cells in ageing. Nature. 2014;509:439–46.CrossRefGoogle Scholar
  18. 18.
    Sturmlechner I, et al. Cellular senescence in renal ageing and disease. Nat Rev Nephrol. 2017;13:77–89.CrossRefGoogle Scholar
  19. 19.
    Anderson R, et al. Mechanisms driving the ageing heart. Exp Gerontol. 2017;109:5–15. Scholar
  20. 20.
    Bartling B. Cellular senescence in normal and premature lung ageing. Z Gerontol Geriat. 2013;46:613–22.CrossRefGoogle Scholar
  21. 21.
    Campisi J, et al. Ageing, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705.CrossRefGoogle Scholar
  22. 22.
    Chilosi M, et al. The pathogenesis of COPD and IPF: distinct horns for the same devil? Respir Res. 2012;13:3.CrossRefGoogle Scholar
  23. 23.
    Schmitt R, et al. Mechanisms of renal ageing. Kidney Int. 2017;92(3):569–79. Scholar
  24. 24.
    Khosla S, et al. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898–907.CrossRefGoogle Scholar
  25. 25.
    Tchkonia T, et al. Cellular senescence and the senescent phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–72.CrossRefGoogle Scholar
  26. 26.
    Dobzhansky T. Nothing in biology makes senses except in the light of evolution. Am Biol Teach. 1973;35:125–9.CrossRefGoogle Scholar
  27. 27.
    Frelin C, et al. Biologie de l’évolution et médecine. Paris: Lavoisier Paris; 2011.Google Scholar
  28. 28.
    Swynghedauw B, editor. Quand le gène est en conflit avec son environnement. Une introduction à la médecine Darwinienne. Bruxelles/Paris: De Boeck; 2009.Google Scholar
  29. 29.
    Burger O. Human mortality improvement in evolutionary context. PNAS. 2012;109:18210–4.CrossRefGoogle Scholar
  30. 30.
    Thomas H. Senescence, ageing and death of the whole plant. New Phytol. 2013;197:696–711.CrossRefGoogle Scholar
  31. 31.
    Thomas H. Senescence. 2016.
  32. 32.
    Kirkwood TB. A systematic look at an old problem. Nature. 2008;451:644–7.CrossRefGoogle Scholar
  33. 33.
    Lakatta EG. So! What’s ageing? Is cardiovascular ageing a disease? J Mol Cell Cardiol. 2015;83:1–13.CrossRefGoogle Scholar
  34. 34.
    Dong X, et al. Evidence for a limit to human lifespan. Nature. 2016;538:257–9. Scholar
  35. 35.
    Vijg J, et al. Puzzles, promises and a cure for ageing. Nature. 2008;454:1065–71.CrossRefGoogle Scholar
  36. 36.
    Kontis V, et al. Future life expectancy in 35 industrialized countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323–35.CrossRefGoogle Scholar
  37. 37.
    Alpérovitch, et al. Do we really know the cause of death of the very old ? Comparison between official mortality statistics and cohort study classification. Eur J Epidemiol. 2009;24:669–75.CrossRefGoogle Scholar
  38. 38.
    Jacqmin-Gadda H, et al. 20-year prevalence projections for dementia and impact of preventive policy about risk factors. Eur J Epidemiol. 2013;28:493–502.CrossRefGoogle Scholar
  39. 39.
    Kohn RR. Cause of death in very old people. JAMA. 1982;247:2793–7.CrossRefGoogle Scholar
  40. 40.
    Vautel JW. Biodemography of human ageing. Nature. 2010;464:536–42.CrossRefGoogle Scholar
  41. 41.
    Creevy KE, et al. The companion dog as a model for the longevity dividend. Cold Spring Harb Perspect Med. 2017;6(1):a026633. Scholar
  42. 42.
    Kirkland JL, et al. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65:2297–301.CrossRefGoogle Scholar
  43. 43.
    Michel JP, et al., editors. Oxford text book of geriatric medicine. 3rd ed. Oxford: Oxford Univ Press; 2018.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bernard Swynghedauw
    • 1
  1. 1.French Institute of Health and Medical ResearchParisFrance

Personalised recommendations